Mobile

A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with aggres...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001888-40

A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Incidence of confirmed leptomeningeal metastasis (CNS relapse) during the post treatment observation period of one year verified by CNS cytology

Critère d'inclusion

  • Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis

Liens